278 completed, 126 unknown, 68 recruiting, 64 terminated. 353 Phase 2, 131 Phase 1, 66 Phase 3, 35 Not applicable, 6 Early Phase 1.
Follow this condition Literature Review of Metastatic Colorectal Cancer trials Research Report on Metastatic Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer AlloStim, Bavencio - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Mirror Biologics, Inc. | 2026-11-01 | 2025-10-21 | |
| Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer Becotatug Vedotin (MRG003), Pucotenlimab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 31 | 2026-10-15 | 2026-10-20 |
| A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM - Metastatic Colorectal Cancer | Phase 1 | Recruiting | Hoffmann-La Roche | 180 | 2026-10-06 | 2026-10-06 |
| A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer DEM301 - Metastatic Colorectal Cancer, Colon Cancer | Phase 1 | Recruiting | DEM BioPharma, Inc. | 60 | 2026-10-01 | 2026-10-15 |
| Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases Dupilumab, Toripalimab - Metastatic Colorectal Cancer, Liver Metastases | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2026-09-01 | 2026-08-12 |
| Circulating Tumor Extracellular Vesicles for Non-Invasive Monitoring of Metastatic Colorectal Cancer Blood sample - Metastatic Colorectal Cancer | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 290 | 2026-09-01 | 2026-08-10 | |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-08-31 | 2026-06-23 |
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland No intervention - Metastatic Colorectal Cancer | Recruiting | Takeda | 110 | 2026-08-13 | 2026-09-22 | |
| Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer S-531011, HD-XRT - Phase II, S-531011 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2026-08-12 | 2026-09-11 | |
| A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI) - Metastatic Colorectal Cancer | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 1020 | 2026-05-06 | 2026-10-08 |
| JS212 Combination Therapies in Metastatic Colorectal Cancer JS212, Capecitabine, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 80 | 2026-04-25 | 2026-05-05 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients EMB-01 1600 mg administered once weekly throughout the study, EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 54 | 2025-12-18 | 2026-03-03 |
| Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) - Metastatic Colorectal Cancer, Oligometastatic Disease | Phase 2 | Suspended | UMC Utrecht | 93 | 2025-12-01 | 2025-03-28 |
| A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC CC-38, Pembrolizumab, Cyclophosphamid - Metastatic Colorectal Cancer, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | CuraCell TX AB | 12 | 2025-11-13 | 2026-06-22 |
| A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. Second and later-line palliative chemotherapy - Metastatic Colorectal Cancer | Recruiting | Boryung Pharmaceutical Co., Ltd | 1000 | 2025-11-07 | 2025-12-04 | |
| New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | The First Hospital of Jilin University | 30 | 2025-11-01 | 2026-04-30 |
| - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases Fruquintinib, Tislelizumab, Trifluridine/tipiracil - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 140 | 2025-10-27 | 2025-12-12 |
Showing 20 of 612. Sign in to see all of them.
Colorectal Neoplasms (612) · Neoplasm Metastasis (51) · Colonic Neoplasms (36) · Neoplasms (32) · Rectal Neoplasms (27) · Breast Neoplasms (14) · Pancreatic Neoplasms (14) · Carcinoma, Hepatocellular (8) · Gastrointestinal Neoplasms (7) · Stomach Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Ovarian Neoplasms (5) · Liver Neoplasms (4) · Lung Neoplasms (4) · Neoplastic Cells, Circulating (4)
Intestinal Neoplasms (611) · Colonic Diseases (610) · Digestive System Diseases (610) · Gastrointestinal Diseases (610) · Intestinal Diseases (610) · Neoplasms by Site (610) · Rectal Diseases (610) · Digestive System Neoplasms (609) · Gastrointestinal Neoplasms (605) · Neoplasms (580) · Pathological Conditions, Signs and Symptoms (57) · Neoplastic Processes (55) · Pathologic Processes (55) · Neoplasms by Histologic Type (24) · Neoplasms, Glandular and Epithelial (24)
Bevacizumab (124) · Irinotecan (105) · Fluorouracil (93) · Oxaliplatin (82) · Leucovorin (79) · Cetuximab (75) · Capecitabine (58) · Panitumumab (41) · IFL protocol (36) · Folfox protocol (29) · regorafenib (27) · trifluridine tipiracil drug combination (27) · HMPL-013 (19) · pembrolizumab (18) · Trifluridine (14)
Amgen (21) · Fudan University (15) · Sun Yat-sen University (13) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (9) · UNICANCER (8) · Bayer (7) · Gruppo Oncologico del Nord-Ovest (7) · Centre Hospitalier Universitaire de Besancon (6) · GERCOR - Multidisciplinary Oncology Cooperative Group (6) · Hoffmann-La Roche (6) · Institut de Recherches Internationales Servier (6) · National Cancer Institute (NCI) (6) · Symphogen A/S (6) · Asan Medical Center (5) · AstraZeneca (5)
United States (152) · China (115) · France (97) · Italy (76) · Spain (75) · Germany (60) · Belgium (49) · United Kingdom (47) · Australia (39) · Canada (39) · South Korea (36) · Austria (25) · Netherlands (25) · Denmark (24) · Poland (24)
Josep Tabernero, MD, PhD (5) · Alfredo Falcone, MD (4) · Norman Wolmark, MD (4) · John Souglakos, MD (3) · Tim F Greten, M.D. (3) · Yanhong Deng, M.D. (3)
PMID 22070868, PMID 26049686, PMID 28712102, PMID 29627309, PMID 31515083, PMID 32816630, PMID 34907230, PMID 36880426, PMID 38592721, PMID 39475591, PMID 39752885, PMID 41252656, PMID 18316791, PMID 18946061, PMID 19287023, PMID 19339720, PMID 20396391, PMID 20921465, PMID 21285134, PMID 22000810, PMID 22396447, PMID 22421192, PMID 22722830, PMID 22782485, PMID 22897915, PMID 23167843, PMID 23177514, PMID 23216781, PMID 23358972, PMID 23359181, PMID 23361051, PMID 23510802, PMID 23532888, PMID 23769817, PMID 23788755, PMID 23922111, PMID 24024839, PMID 24114613, PMID 24138831, PMID 24173967, PMID 24407191, PMID 24755296, PMID 24812403, PMID 24884501, PMID 25038824, PMID 25319061, PMID 25335932, PMID 25605843, PMID 25628445, PMID 25703078
2009 (8), 2019 (8), 2016 (6), 2015 (5), 2017 (5), 2018 (5), 2025 (5), 2008 (3), 2023 (3), 2014 (2), 1UG1CA189823-01 (1), K08CA267313 (1), R01CA107088 (1), R44CA250824 (1), U54CA156732 (1)